Article Body
Shares of Divi's Laboratories are expected to remain in focus on Monday after the pharmaceutical company reported its Q4 FY26 earnings, posting steady growth in profit and revenue on a year-on-year basis. The company also announced a final dividend recommendation of ₹30 per share for FY26.
The strong quarterly performance was supported by healthy demand across its active pharmaceutical ingredients (API) and custom synthesis business segments.
Divi’s Laboratories Q4 FY26 Results
Divi’s Laboratories reported a consolidated net profit of ₹751 crore in the fourth quarter of FY26, registering a growth of 13.4% compared to ₹662 crore reported in the corresponding quarter last year.
Revenue from operations rose 9.5% year-on-year to ₹2,831 crore against ₹2,585 crore in Q4 FY25, reflecting stable business momentum and improved operational performance.
The company’s EBITDA increased 5.4% to ₹934 crore compared to ₹886 crore in the year-ago quarter. However, EBITDA margin slipped to 33% from 34.3% on a YoY basis, indicating some pressure on operating profitability.
Dividend Announcement
The board of Divi’s Laboratories recommended a final dividend of ₹30 per equity share for FY26, subject to shareholder approval at the upcoming annual general meeting.
The dividend announcement is likely to remain a key trigger for investor sentiment in the near term.
Divi’s Laboratories Share Price Performance
On Friday, Divi’s Laboratories stock closed at ₹6,887, up 0.42% from the previous close of ₹6,858 on the stock market.
The stock touched an intraday high of ₹6,960.50 and a low of ₹6,790 during the session.
Over the past 52 weeks, the stock has recorded a high of ₹7,071.50 and a low of ₹5,636.50, reflecting strong long-term momentum in the pharmaceutical counter.
Disclaimer: The information provided in this article is for informational and educational purposes only and should not be construed as financial, investment, or trading advice. Stock market investments are subject to market risks, and past performance does not guarantee future results. Readers are advised to conduct their own research and consult with a qualified financial advisor before making any investment decisions. The publication and the author are not responsible for any losses incurred based on the information provided in this article.
Comments